Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

whereas vaccines prompt the body’s immune system to produce an immune response itself. The meta-analysis of 27 studies conducted during the 2023-2024 RSV season across five countries (France ...

HHS and the National Institutes of Health are developing a project that involves producing vaccines from chemically inactivated whole viruses with the goal of making “universal” vaccines that protect ...

The Therapeutic Goods Association recently expanded approval for the RSV vaccine AREXVY to include Australians aged 50 and older with chronic health and respiratory conditions. Vulnerable people ...